TB-500's parent protein has stronger human data than GHK-Cu or BPC-157

Has anyone tested GHK-Cu, BPC-157 and TB-500 together?

No study has tested GHK-Cu, BPC-157 and TB-500 together, in humans or in any other species. A 2026 orthopedic and sports medicine review that evaluates all three agents states directly that the evidence behind injectable peptide combinations like this one is lacking ^[7]. Whether the three-peptide stack outperforms BPC-157 and TB-500 without GHK-Cu is also unknown, because that head-to-head has never been published. The two-peptide BPC-157 and TB-500 combination is analyzed separately.

Combining the three on paper does not raise the evidence grade of any of them. The stack pairs a peptide with small controlled human trials (thymosin beta-4, not TB-500 specifically), a peptide with topical-only controlled human trials (GHK-Cu), and a peptide with essentially no controlled human trials (BPC-157). That does not average out to one solid evidence base. It produces three separate risk profiles running in parallel, none of which has been tested for what happens when they meet in the same bloodstream.

What is each peptide in the stack claimed to do?

GHK-Cu, BPC-157 and TB-500 each come with a separate mechanistic story, and the three sound complementary only if nobody looks too closely. BPC-157 is described as supporting tendon and muscle repair through effects on blood vessel growth and tissue signaling.

TB-500 is marketed as the synthetic fragment of thymosin beta-4, a naturally occurring protein studied for its role in cell migration. In topical wound care, researchers describe the intact protein's proposed action as promoting keratinocyte and endothelial cell migration, increasing collagen deposition, and stimulating new blood vessel formation ^[6]. The clinical trial record belongs to that intact protein, and TB-500 is not the same molecule as thymosin beta-4.

GHK-Cu is a copper-binding tripeptide. Its proposed activity involves copper-dependent biochemistry alongside skin-remodeling signals.

What human trials exist for thymosin beta-4 and TB-500?

Thymosin beta-4, the intact 43-amino-acid parent protein of TB-500, has small but real phase 1 and phase 2 randomized controlled trials. That record belongs to the intact protein, not the TB-500 fragment. Dose-escalation intravenous studies found single and multiple doses well tolerated, with no dose-limiting toxicity ^[1]⁠^[5]. A nine-patient phase 2 dry eye trial showed statistically significant improvement in comfort and corneal staining scores ^[2]. Dose-escalation venous ulcer trials described an acceptable safety profile and healing in roughly a quarter of treated patients with small to moderate wounds ^[6].

That is a legitimate evidence base for thymosin beta-4: small, but real. Grade matters more than volume, and none of those trials tested the fragment sold as TB-500.

Has GHK-Cu been tested as an injection?

No controlled human trial has tested injected GHK-Cu, so its evidence grade is low for the question that matters to an injector. GHK-Cu's controlled human data come entirely from topical use. In a randomized trial of post-laser skin care, GHK-Cu did not produce a statistically significant reduction in erythema compared with control on the objective, computer-scored endpoint; a difference showed up only on a subjective patient questionnaire ^[3].

That is a real finding, but it describes a cream applied to resurfaced skin, not an injected dose aimed at connective tissue. Even on resurfaced skin, the primary objective measure did not separate from control ^[3]. The gap between topical and injectable GHK-Cu evidence is analyzed separately.

What human evidence supports BPC-157?

BPC-157's human support, as a 2026 review of injectable peptide therapy in orthopedic practice describes it, is a single case series with significant methodological limitations, not a controlled trial ^[7]. That review, the most recent to cover BPC-157 alongside thymosin beta-4 and GHK-Cu, calls BPC-157's tendon and muscle repair findings "largely unvalidated in human trials," with the one human case series limited by a lack of controls ^[7].

BPC-157 therefore sits at the bottom of the grading scale among the three peptides. BPC-157's human record is covered in a separate analysis.

Do the stack's overlapping pathways add up or compete?

Nobody knows whether GHK-Cu, BPC-157 and TB-500 add to, duplicate, or blunt each other's effects, because no one has run the comparison. The synergy pitch assumes the three agents hit complementary targets. The pathways described for thymosin beta-4, cell migration, collagen deposition, and blood vessel formation ^[6], overlap substantially with the pathways proposed for BPC-157 and GHK-Cu.

Overlapping pathways can behave in at least three ways, and no study distinguishes which one applies to this stack:

• Additive. Each agent adds to the effect of the others.
• Redundant. The second and third agents add nothing, because the first already saturated the pathway.
• Competing. The agents compete for the same signaling machinery and blunt each other.

The copper chemistry adds an open variable. GHK-Cu's proposed activity depends partly on copper-driven redox chemistry, and introducing that into a mix with two peptides that influence angiogenic and inflammatory signaling raises an interaction question that has not been examined at any level, human or animal. That is not a reason to assume harm. It is a reason to admit the question has never been asked.

Where do the online doses for this stack come from?

The online doses for GHK-Cu, BPC-157 and TB-500 do not trace to any cited study, whether for the TB-500 fragment, the combination, or the injectable route in the case of GHK-Cu. Community protocols describing GHK-Cu at around 1 to 2 milligrams daily, BPC-157 in the 250 to 500 microgram range, and TB-500 loaded at 2 to 5 milligrams weekly circulate widely online. No study specifies injectable dosing for this three-agent combination.

The trial doses for intact thymosin beta-4 look different. The recombinant thymosin beta-4 safety trial used intravenous doses ranging from 0.05 to 25.0 micrograms per kilogram in single-dose cohorts, and up to 5.0 micrograms per kilogram daily for ten days in the multiple-dose cohort, with no dose-limiting toxicity observed ^[1]. A separate synthetic thymosin beta-4 trial tested single and 14-day daily intravenous doses across a much higher range, up to 1260 milligrams, also without dose-limiting toxicity ^[5]. Those are pharmaceutical-grade trials with defined, published doses for the intact protein.

Some protocols also describe a compressed acronym as though it were a validated product. That acronym marks a marketing category, not a tested formulation, and no study evaluates it as a unit.

What is still unknown about the GHK-Cu, BPC-157 and TB-500 stack?

Three questions about the GHK-Cu, BPC-157 and TB-500 stack remain unresolved:

• The TB-500 fragment. Whether TB-500 as an isolated fragment reproduces the pharmacokinetics and safety profile established for intact thymosin beta-4 in controlled trials ^[1]⁠^[5] is not answered by those trials, and neither is whether the fragment behaves the same way at the doses sold online.
• Injected GHK-Cu. Whether GHK-Cu behaves the same way injected as it does applied topically to resurfaced skin ^[3] has not been tested.
• The combination. Whether combining all three produces additive, redundant, or competing effects on overlapping repair pathways has never been studied in any species, a gap the most recent review of injectable peptide therapy states outright ^[7].

The test for the next citation-free protocol is whether its claim concerns the exact combination being sold, or one ingredient tested alone in a different route, dose, or species. Those are different claims, and only the single-ingredient claim is currently answerable with data.